ReviewFrontiers in pharmacology2025
A review of advances in the treatment of diabetic nephropathy by modulating intestinal flora with natural products of traditional Chinese medicine.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Nephropathy (DN) is one of the most serious complications of diabetes mellitus (DM). Hemodynamic irregularities, metabolic problems, and hormone production are only a few of the many mediators and routes that contribute to the intricate and varied genesis of DN. DN is the most common cause of end-stage renal disease, which is characterised by persistently low glomerular filtration capacity and hyperglycaemia. Numerous studies have been conducted recently on the function of gut flora in DN. According to current research, the formation and progression of DN have been linked to imbalances in the gut microbiota and abnormal microbial metabolite production. Therefore, intestinal flora modulation may be an entry point for the treatment of DN. As an increasing number of studies are using natural products of traditional Chinese medicine (TCM) as a therapeutic tool, this article reviews the progress of TCM natural products in treating DN by modulating gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.